Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGLTS:0QW5 -0.81%19 Net-Net Working Capital is €-0.66 as of May. 2026. GuruFocus rates LTS:0QW5 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 845 Biotechnology companies, Heidelberg Pharma AG ranks worse than 118343.08% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Heidelberg Pharma AG's Net-Net Working Capital for the quarter that ended in May. 2026 was €-0.66.
The industry rank for Heidelberg Pharma AG's Net-Net Working Capital or its related term are showing as below:
LTS:0QW5's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 5.21 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Heidelberg Pharma AG (LTS:0QW5) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Heidelberg Pharma AG Net-Net Working Capital Related Terms
Heidelberg Pharma AG Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG Net-Net Working Capital Chart
LTS:0QW5 vs VRTX, REGN, MRNA: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of €-0.66 mean?
Heidelberg Pharma AG (LTS:0QW5) has a Net-Net Working Capital of €-0.66 as of May. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Heidelberg Pharma AG According to the industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 845 companies in the Biotechnology industry.
Is Heidelberg Pharma AG's Net-Net Working Capital too high?
Heidelberg Pharma AG's current Net-Net Working Capital is €-0.66. Based on the distribution chart, Heidelberg Pharma AG ranks #999999 out of 845 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #999999 out of 845 companies for Net-Net Working Capital. This places Heidelberg Pharma AG in the lower half of its industry. The industry median Net-Net Working Capital is 5.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.21, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Heidelberg Pharma AG For the Biotechnology industry, the median Net-Net Working Capital is 5.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Net-Net Working Capital is €-0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Heidelberg Pharma AG (LTS:0QW5) has a current Net-Net Working Capital of €-0.66. The current Net-Net Working Capital is €-0.66. Heidelberg Pharma AG's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Heidelberg Pharma AG (LTS:0QW5), the current Net-Net Working Capital is €-0.66 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
19GF Score
Get the complete analysis for LTS:0QW5
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QW5 has been successfully added to your 
